RenovoRx

01/14/2026

RenovoRx CEO Shaun Bagai will be participating in the AlphaNorth Capital Event this weekend, where he will share an update on key milestones and recent progress across RenovoRx’s commercial and clinical programs. For more information: https://bit.ly/4pCQAsY

01/13/2026

Join us on Tuesday, January 20th at 5:00 PM PT for the TAMP (Trans-Arterial Micro-Perfusion) Peer-to-Peer Best Practices Workshop to gain valuable insights into the TAMP therapy platform, enabled by the RenovoCath® device, designed to enable targeted locoregional therapeutic delivery. Register here: https://bit.ly/4pidDcp

01/12/2026

In an article for OncLive, Dr. Gregory Tiesi, Medical Director of Hepatobiliary Surgery at Hackensack Meridian Jersey Shore University Medical Center, highlighted the limitations of current systemic therapies for solid tumors, like , and the potential for RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform to improve cancer patient outcomes. Read more: https://bit.ly/4saF0YD

Pancreatic ductal adenocarcinoma remains highly lethal due to late presentation, treatment resistance, and limited drug delivery with standard systemic therapies.

01/09/2026

We’re proud to share that new clinical data featuring RenovoRx’s TAMP™ therapy platform will be presented at American Society of Clinical Oncology (ASCO) GI 2026. Read the full abstract here: https://bit.ly/45BP0jX

01/08/2026

RenovoRx today announced that a clinical data abstract with new pharmacokinetic and pharmacodynamic data from a sub-study in its Phase III trial, strengthening the scientific basis for RenovoRx’s TAMP therapy platform, will be presented at ASCO GI 2026. The symposium is being held today through January 10th in San Francisco, CA. The data shows a PK profile that may improve clinical efficacy and decrease clinical side effects with TAMP and intra-arterial gemcitabine versus standard of care chemotherapy. For details: https://bit.ly/4qctDhx

01/05/2026

RenovoRx will host the TAMP (Trans-Arterial Micro-Perfusion) Peer-to-Peer Best Practices Workshop on Tuesday, January 20 at 5:00 PM PT, with cases presented by Dr. Mustafa Al-Roubaie and Dr. Anil Pillai, and discussion moderated by Dr. Ripal Gandhi and Dr. Paula Novelli. This educational workshop is an interactive peer-to-peer forum designed for physicians to share their experiences, including case presentations, with the TAMP therapy platform, enabled by the RenovoCath® device. Register for the workshop here: https://bit.ly/4pidDcp

12/16/2025

Spectrum News 1 SoCal recently featured an interview with Dr. Jonathan Kessler, Chief of Interventional Radiology at City of Hope, highlighting how RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform, enabled by the RenovoCath® device, has the potential to reshape oncology management for patients diagnosed with difficult-to-treat tumors, like . Learn more: https://bit.ly/3KZYjmN

*RenovoCath is currently cleared for the indication below. The Company is evaluating its novel combination oncology product candidate (intra-arterial gemcitabine, known as IAG) in the ongoing Phase III TIGeR-PaC trial. IAG is being evaluated by the Center for Drug Evaluation and Research (the drug division of FDA) under a U.S. investigational new drug application that is regulated by the FDA’s 21 CFR 312 pathway. Based on completed studies, intra-arterial delivery of chemotherapy via Trans-Arterial Micro-Perfusion (TAMP™), which targets delivery of treatment in proximity to the tumor tissue within the pancreas using the vasa vasorum pathway, reduced tolerability issues associated with systemic chemotherapy and presented early signals of improved patient survival. The study, called TIGeR-PaC (“Intra-Arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC”), is the evaluating the combination oncology product candidate (IAG) which is not yet approved by FDA for this use and not yet available for commercial sale. Indication for Use: RenovoCath is intended for the isolation of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to selected sites in the peripheral vascular system. RenovoCath is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. RenovoCath is intended for general intravascular use in the peripheral vasculature in arteries 3mm and larger. The RenovoCath is intended for use in arteries from 3mm in diameter for vessel entry and to occlude vessels ranging between 3mm to 11mm in diameter. The diagnostic and/or therapeutic agents are to be used in accordance with specifications outlined by the respective agent manufacturer. For detailed information on RenovoCath including warnings, precautions, and contraindications, please refer to the product IFU on the RenovoRx website: https://bit.ly/44Z4rm0

12/11/2025

Dr. Ramtin Agah, RenovoRx’s Chief Medical Officer, comments on the Company's accepted abstract for the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium 2026. For more info, visit: https://bit.ly/4q6Uxac

12/11/2025

RenovoRx is pleased to announce that its abstract submission to the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium 2026 has been accepted. The accepted abstract provides supportive evidence for the TAMP™ therapy platform’s novel, localized approach to targeted chemotherapeutic delivery via additional pharmacokinetic and pharmacodynamic data. The findings from a sub-study of the ongoing Phase III TIGeR-PaC clinical trial will be presented January 9, 2026, at 11:30 AM-1:00 PM PT and 5:00-6:00 PM PT. For details: https://bit.ly/4q6Uxac

12/09/2025

Tune-in today, December 9th at 12:30 P.M. ET for RenovoRx CEO, Shaun Bagai's presentation at the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025. Shaun will share updates on RenovoRx’s continued commercial efforts and market traction for the RenovoCath® device, along with the latest developments in the Company’s Phase III TIGeR-PaC clinical trial and post-marketing registry study. For webcast details: https://bit.ly/3XygbI6

12/08/2025

Our CEO, Shaun Bagai, joined MedTech101 to discuss how RenovoRx is potentially changing the treatment landscape for patients diagnosed with difficult-to-treat tumors, like pancreatic cancer. Our patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform, enabled by the RenovoCath® device, offers an innovative approach to drug-delivery that can increase local drug concentration versus systemic intravenous therapy, while potentially minimizing toxicities and improving quality of life for patients. Listen here: https://bit.ly/3KdpPgn

12/05/2025

Reminder: RenovoRx CEO, Shaun Bagai, will present at the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on Tuesday, December 9th at 12:30 P.M. ET. For webcast details, visit: https://bit.ly/3XygbI6